Reach Us 44-1522-440391
CD133-positive Status Predicts Better Prognosis in Metastatic Colorectal Cancer Patients Treated with Cetuximab | OMICS International | Abstract
ISSN: 2157-7099

Journal of Cytology & Histology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

CD133-positive Status Predicts Better Prognosis in Metastatic Colorectal Cancer Patients Treated with Cetuximab

Dai Inoue1, Satoshi Matsusaka1,3*, Noiriko Yamamoto2, Mitsukuni Suenaga1, Eiji Shinozaki1, Nobuyuki Mizunuma1, Yuichi Ishikawa2 and Kiyohiko Hatake3

1Department of Gastroenterology, Cancer Institute Hospital, Japan

2Department of Pathology, Cancer Institute Hospital, Japan

3Clinical Chemotherapy, Cancer Chemotherapy Center of Japanese Foundation for Cancer Research, Japan

*Corresponding Author:
Satoshi Matsusaka
3-8-31 Ariake, Koto-ku
Tokyo 135-8550, Japan
Tel: +81-3-3520-0111
Fax: +81-3-3570-0343
E-mail: [email protected]

Received Date: November 13, 2013; Accepted Date: December 04, 2013; Published Date: December 06, 2013

Citation: Inoue D, Matsusaka S, Yamamoto N, Suenaga M, Shinozaki E, et al. (2013) CD133-positive Status Predicts Better Prognosis in Metastatic Colorectal Cancer Patients Treated with Cetuximab. J Cytol Histol 5:202. doi:10.4172/2157-7099.1000202

Copyright: © 2013 Inoue D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: There are few evidence which kind of tumor is more benefit from cetuximab, more investigations of supplementary predictive factors are highly relevant. The purpose is to evaluate the prognostic significance of CD133 expression and to investigate the utility as biomarker of prognosis of metastatic colorectal cancer (mCRC) patients treated with cetuximab. Methods: We investigated progression-free survival (PFS) and overall survival (OS) of patients with mCRC about 5FU-based regimen as first line chemotherapy and cetuximab as salvage line retrospectively, and performed immunohistochemical staining to evaluate the CD133 status. Non-parametric statistics, univariate and multivariate analysis were used. Results: From October 2008 to June 2009, 46 patients with measurable mCRC had received cetuximab as salvage line, and all of them had treated with 5FU-based regimen as first line. In first line chemotherapy, the median OS was 33.1 months (95% CI, 25.6-40.4) in the CD133-positive patients as compared with 16.0 months (95% CI, 0.938-31.1) in the CD133-negative patients (P=0.004), but there were no statistically significant difference in PFS between both group. In salvage therapy with cetuximab, the median OS was 8.8 months (95% CI, 5.24-12.4) in the CD133-positive patients as compared with 5.1 months (95% CI, 3.23-6.90) in the CD133-negative patients (P=0.007). The median PFS was also significantly better in CD133-positive patients, with a median of 5.2 month (95% CI, 2.96-7.51) in the CD133-positive patients as compared with 2.8 month (95% CI, 1.48-4.06) in CD133- negative patients (P=0.046). Univariate and multivariate Cox proportional hazards regression was performed, and it is shown that CD133 predicted OS and PFS of cetuximab. Conclusions: CD133 status was correlated with the prognosis of patients